Literature DB >> 9155043

Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes.

Y Hatta1, S Takeuchi, J Yokota, H P Koeffler.   

Abstract

Identification of the key genetic alterations leading to ovarian cancer is in its infancy. Polymerase chain reaction (PCR)-based analysis of loss of heterozygosity (LOH) is a powerful method for detecting regions of altered tumour-suppressor genes. Focusing on chromosome 12, we examined 23 ovarian cancer samples for LOH using 31 highly polymorphic microsatellite markers and found the chromosomal localization of two putative tumour-suppressor genes. Two commonly deleted regions were 12p12.3-13.1 in 6/23 (26%) and 12q23-ter in 7/23 (30%) samples. LOH on chromosome 12 was more common in late-stage ovarian carcinomas. The region of LOH at 12p12.3-13.1 includes the genes that code for the ETS-family transcriptional factor, known as TEL, and the cyclin-dependent kinase inhibitor, known as p27Kip1. Mutational analysis of both TEL and p27Kip1 using single-strand conformation polymorphism (SSCP) showed no abnormalities, suggesting that the altered gene in this region is neither of these genes. Taken together, our data suggest that new tumour-suppressor genes in the region of chromosomes 12p12.3-13.1 and 12q23-ter may be involved in the development of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9155043      PMCID: PMC2228239          DOI: 10.1038/bjc.1997.214

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  55 in total

1.  Structural organization of the human neuronal nitric oxide synthase gene (NOS1).

Authors:  A V Hall; H Antoniou; Y Wang; A H Cheung; A M Arbus; S L Olson; W C Lu; C L Kau; P A Marsden
Journal:  J Biol Chem       Date:  1994-12-30       Impact factor: 5.157

2.  The novel activation of ABL by fusion to an ets-related gene, TEL.

Authors:  P Papadopoulos; S A Ridge; C A Boucher; C Stocking; L M Wiedemann
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

3.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

4.  Mutations and altered expression of p16INK4 in human cancer.

Authors:  A Okamoto; D J Demetrick; E A Spillare; K Hagiwara; S P Hussain; W P Bennett; K Forrester; B Gerwin; M Serrano; D H Beach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

5.  Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11.

Authors:  A Buijs; S Sherr; S van Baal; S van Bezouw; D van der Plas; A Geurts van Kessel; P Riegman; R Lekanne Deprez; E Zwarthoff; A Hagemeijer
Journal:  Oncogene       Date:  1995-04-20       Impact factor: 9.867

6.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors.

Authors:  M V Ponce-Castañeda; M H Lee; E Latres; K Polyak; L Lacombe; K Montgomery; S Mathew; K Krauter; J Sheinfeld; J Massague
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

7.  Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer.

Authors:  F Bullrich; T K MacLachlan; N Sang; T Druck; M L Veronese; S L Allen; N Chiorazzi; A Koff; K Heubner; C M Croce
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

8.  Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias.

Authors:  J A Pietenpol; S K Bohlander; Y Sato; N Papadopoulos; B Liu; C Friedman; B J Trask; J M Roberts; K W Kinzler; J D Rowley
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

9.  Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia.

Authors:  Y Hatta; T Hirama; C W Miller; Y Yamada; M Tomonaga; H P Koeffler
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

10.  TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13).

Authors:  I Wlodarska; C Mecucci; P Marynen; C Guo; D Franckx; R La Starza; A Aventin; A Bosly; M F Martelli; J J Cassiman
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

View more
  9 in total

1.  Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer.

Authors:  Coya Tapia; Inti Zlobec; Sandra Schneider; Ergin Kilic; Uwe Güth; Lukas Bubendorf; Suwon Kim
Journal:  Hum Pathol       Date:  2011-02-11       Impact factor: 3.466

2.  TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1.

Authors:  R Fenrick; L Wang; J Nip; J M Amann; R J Rooney; J Walker-Daniels; H C Crawford; D L Hulboy; M S Kinch; L M Matrisian; S W Hiebert
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

3.  A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer.

Authors:  Suwon Kim; Koei Chin; Joe W Gray; J Michael Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-04       Impact factor: 11.205

Review 4.  The WNKs: atypical protein kinases with pleiotropic actions.

Authors:  James A McCormick; David H Ellison
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 5.  Cancer and forensic microsatellites.

Authors:  Karen Page; Eleanor A M Graham
Journal:  Forensic Sci Med Pathol       Date:  2008-02-02       Impact factor: 2.007

6.  Loss of Bcl-G, a Bcl-2 family member, augments the development of inflammation-associated colorectal cancer.

Authors:  Paul M Nguyen; Laura F Dagley; Adele Preaudet; Philippe Bouillet; Tracy L Putoczki; Nga Lam; Maybelline Giam; Ka Yee Fung; Kaheina Aizel; Gemma van Duijneveldt; Chin Wee Tan; Yumiko Hirokawa; Hon Yan K Yip; Christopher G Love; Ashleigh R Poh; Akshay D' Cruz; Charlotte Burstroem; Rebecca Feltham; Suad M Abdirahman; Kristy Meiselbach; Ronnie Ren Jie Low; Michelle Palmieri; Matthias Ernst; Andrew I Webb; Tony Burgess; Oliver M Sieber
Journal:  Cell Death Differ       Date:  2019-07-11       Impact factor: 15.828

7.  Somatic mutation of CDKN1B in small intestine neuroendocrine tumors.

Authors:  Joshua M Francis; Adam Kiezun; Alex H Ramos; Stefano Serra; Chandra Sekhar Pedamallu; Zhi Rong Qian; Michaela S Banck; Rahul Kanwar; Amit A Kulkarni; Anna Karpathakis; Veronica Manzo; Tanupriya Contractor; Juliet Philips; Elizabeth Nickerson; Nam Pho; Susanne M Hooshmand; Lauren K Brais; Michael S Lawrence; Trevor Pugh; Aaron McKenna; Andrey Sivachenko; Kristian Cibulskis; Scott L Carter; Akinyemi I Ojesina; Samuel Freeman; Robert T Jones; Douglas Voet; Gordon Saksena; Daniel Auclair; Robert Onofrio; Erica Shefler; Carrie Sougnez; Jonna Grimsby; Lisa Green; Niall Lennon; Tim Meyer; Martyn Caplin; Daniel C Chung; Andreas S Beutler; Shuji Ogino; Christina Thirlwell; Ramesh Shivdasani; Sylvia L Asa; Chris R Harris; Gad Getz; Matthew Kulke; Matthew Meyerson
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

8.  Is PML a Tumor Suppressor?

Authors:  Massimiliano Mazza; Pier Giuseppe Pelicci
Journal:  Front Oncol       Date:  2013-07-09       Impact factor: 6.244

9.  Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer.

Authors:  Yuan-Chin Tsai; Tao Zeng; Wassim Abou-Kheir; Hsiu-Lien Yeh; Juan Juan Yin; Yi-Chao Lee; Wei-Yu Chen; Yen-Nien Liu
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.